Findling Robert L, Steiner Hans, Weller Elizabeth B
Department of Psychiatry, University Hospitals of Cleveland, Cleveland, Ohio 44106-5080, USA.
J Clin Psychiatry. 2005;66 Suppl 7:29-40.
The comparable efficacy and improved safety of the atypical antipsychotics compared with the traditional antipsychotic agents in the treatment of schizophrenia and other disorders in adults have prompted the use of these agents in children and adolescents. The atypical antipsychotics are increasingly being used in children and adolescents with a variety of different psychiatric diagnoses, including schizophrenia, bipolar disorder, autism/pervasive developmental disorders, conduct disorder, depression, anxiety disorders, tic disorders, delirium, and eating disorders. Unfortunately, clinical use of these agents in pediatric patients has far exceeded the limited evidence from randomized controlled trials. This article reviews the available evidence from the published literature on the use of the atypical antipsychotics in children and adolescents with schizophrenia, bipolar disorder, and maladaptive aggression associated with autism/pervasive developmental disorders and conduct disorder/disruptive behavior disorders.
与传统抗精神病药物相比,非典型抗精神病药物在治疗成人精神分裂症及其他疾病方面具有相当的疗效且安全性更佳,这促使人们将这些药物用于儿童和青少年。非典型抗精神病药物越来越多地用于患有各种不同精神疾病诊断的儿童和青少年,包括精神分裂症、双相情感障碍、自闭症/广泛性发育障碍、品行障碍、抑郁症、焦虑症、抽动障碍、谵妄和饮食失调。不幸的是,这些药物在儿科患者中的临床应用远远超出了随机对照试验的有限证据。本文回顾了已发表文献中关于非典型抗精神病药物用于患有精神分裂症、双相情感障碍以及与自闭症/广泛性发育障碍和品行障碍/破坏性行为障碍相关的适应不良攻击行为的儿童和青少年的现有证据。